Each filer's latest filing for 71722W107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Frazier Life Sciences Public Fund, L.P.
13D/A
|
7.4% |
11/2/2026
Event 10/29/2026
|
||
| Frazier Life Sciences Public Fund, L.P. | 6.5% | |||
| FHMLSP, L.P. | 6.5% | |||
| FHMLSP, L.L.C. | 6.5% | |||
| Frazier Life Sciences X, L.P. | 0.1% | |||
| FHMLS X, L.P. | 0.1% | |||
| FHMLS X, L.L.C. | 0.1% | |||
| Frazier Life Sciences XI, L.P. | 1.2% | |||
| FHMLS XI, L.P. | 1.2% | |||
| FHMLS XI, L.L.C. | 1.2% | |||
| Frazier Life Sciences IX, L.P. | 7.2% | |||
| FHMLS IX, L.P. | 7.2% | |||
| FHMLS IX, L.L.C. | 7.2% | |||
| Frazier Life Sciences XII, L.P. | 0.3% | |||
| FHMLS XII, L.P. | 0.3% | |||
| FHMLS XII, L.L.C. | 0.3% | |||
| James N. Topper | 7.4% | |||
| Patrick J. Heron | 7.3% | |||
| BlackRock, Inc. 13G | 5.5% |
7/29/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (5) | ||||
|
Carlyle Group Inc.
13G/A
|
4.9% |
8/28/2025
Event 8/28/2025
|
||
| Carlyle Group Inc. | 4.9% | |||
| Carlyle Holdings I GP Inc. | 4.9% | |||
| Carlyle Holdings I GP Sub L.L.C. | 4.9% | |||
| Carlyle Holdings I L.P. | 4.9% | |||
| CG Subsidiary Holdings L.L.C. | 4.9% | |||
| TC Group, L.L.C. | 4.9% | |||
| Carlyle Investment Management L.L.C. | 4.9% | |||
| Carlyle Genesis UK LLC | 4.9% | |||
| Abingworth LLP | 4.9% | |||
| Abingworth Bioventures 8 LP | 2.9% | |||
| Abingworth Bioventures VII LP | 2.0% | |||
|
Millennium Management LLC
13G/A
|
4.2% |
7/20/2026
Event 6/30/2026
|
||
| Millennium Management LLC | 4.2% | |||
| Millennium Group Management LLC | 4.2% | |||
| Israel A. Englander | 4.2% | |||
| Invesco Ltd. 13G/A | 0% |
11/10/2026
Event 9/30/2026
|
||
| Prudential Financial Inc 13G/A | 0% |
6/6/2025
Event 5/31/2025
|
||
| Jennison Associates LLC 13G/A | 0% |
6/9/2025
Event 5/31/2025
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 164 | 70.3 M | $509M |
| 2026 Q2 | 163 | 72.1 M | $782M |
| 2026 Q1 | 177 | 69.2 M | $768M |
| 2025 Q4 | 174 | 62.0 M | $1.03B |
| 2025 Q3 | 134 | 62.3 M | $734M |
| 2025 Q2 | 122 | 57.4 M | $551M |
| 2025 Q1 | 139 | 64.0 M | $401M |
| 2024 Q4 | 145 | 66.7 M | $541M |
| 2024 Q3 | 134 | 72.6 M | $1.31B |
| 2024 Q2 | 116 | 58.1 M | $599M |
| 2024 Q1 | 116 | 55.4 M | $588M |
| 2023 Q4 | 119 | 54.1 M | $503M |
| 2023 Q3 | 112 | 43.8 M | $453M |
| 2023 Q2 | 104 | 42.8 M | $613M |
| 2023 Q1 | 85 | 30.8 M | $220M |
| 2022 Q4 | 89 | 28.4 M | $318M |
| 2022 Q3 | 96 | 30.2 M | $334M |
| 2022 Q2 | 96 | 27.3 M | $237M |
| 2022 Q1 | 86 | 25.7 M | $350M |
| 2021 Q4 | 85 | 28.6 M | $562M |
| 2021 Q3 | 85 | 25.5 M | $820M |
| 2021 Q2 | 81 | 24.9 M | $844M |
| 2021 Q1 | 85 | 24.5 M | $919M |
| 2020 Q4 | 77 | 24.5 M | $815M |
| 2020 Q3 | 59 | 21.6 M | $794M |
| 2020 Q2 | 62 | 21.8 M | $719M |
| 2020 Q1 | 48 | 21.9 M | $566M |
| 2019 Q4 | 41 | 21.8 M | $677M |